NICE News
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer
BTOG wishes to inform members of a new NICE release that has been published today. Following review of the original technical appraisal, NICE...
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended serplulimab with carboplatin and...
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended cemiplimab with platinum-based...
Amivantamab with carboplatin and pemetrexed during the managed access period as an option for untreated advanced NSCLC with activating ex20ins mutations in adults
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab with carboplatin and...
Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended osimertinib, within its marketing...
Encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced NSCLC
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended encorafenib plus binimetinib as an...
New guidance recommends Nivolumab to treat resectable NSCLC
BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then...
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended amivantamab plus lazertinib, within its...
Lorlatinib update
BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Lorlatinib as an option for ALK-positive...
Durvalumab update
BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing...
Osimertinib update
BTOG can confirm that NICE has released draft guidance as follows: Osimertinib should not be used for the maintenance treatment of locally advanced...
Cemiplimab update
BTOG can confirm that NICE has released guidance as follows: Cemiplimab with platinum-based chemotherapy should not be used for untreated...
Osimertinib with pemetrexed and platinum-based chemotherapy based on the FLAURA2 trial
BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Osimertinib with pemetrexed and...
Durvalumab for treatment of untreated extensive-stage small-cell lung cancer
BTOG can confirm that NICE has recommended durvalumab with etoposide and either carboplatin or cisplatin, as an option for untreated extensive-stage...
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
BTOG can confirm that NICE has recommended pembrolizumab, within its marketing authorisation, as an option for the adjuvant treatment of...
Durvalumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer
BTOG can confirm that NICE has recommended durvalumab within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy,...
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer
BTOG can confirm that NICE has recommended Pembrolizumab, within its marketing authorisation, as an option for neoadjuvant treatment with...
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
BTOG can confirm that NICE has recommended alectinib, within its marketing authorisation, as an option for the adjuvant treatment of stage 1B...
NICE Update: Systemic anti-cancer therapy for advanced non-small-cell lung cancer, treatment options
NICE has published an update to the NICE Systemic anti-cancer therapy for advanced non‑small‑cell lung cancer: treatment options summary (PDF).
New NICE Result: Lorlatinib
BTOG is disappointed that lorlatinib has not been recommended, within its marketing authorisation, for treating anaplastic lymphoma kinase...